Articles published by Merck & Co., Inc.

...

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

June 17, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

June 12, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Animal Health to Acquire TARGAN

June 11, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

June 08, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers GILD MRK

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 02, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 29, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Third-Quarter 2026 Dividend

May 26, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 22, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 18, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

May 12, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

May 07, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 05, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK TERN

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

April 30, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

April 28, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

April 24, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

April 21, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

April 21, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

April 17, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 07, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 01, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

March 25, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

March 18, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

March 16, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.